- Practice Area
- Administrative Law
- Admiralty & Maritime Law
- Advertising Law
- Alternative Dispute Resolution
- AmLaw 200 Blogs
- Antitrust Law
- Civil Rights & Privacy Law
- Consumer Law
- Corporate & Commercial Litigation
- Criminal Law
- Divorce & Family Law
- Education Law
- Election Law & Political Commentary
- Electronic Discovery
- Employment & Labor Law
- Environmental Law
- General Counsel Blogs
- Immigration Law
- Insurance Law
- Intellectual Property Law
- International Law
- Judiciary Law
- Media, Entertainment & Sports Law
- Law Firm Management & Legal Marketing
- Personal Injury & Medical Law
- Probate & Estate Planning
- Real Estate & Construction Law
- Tax & Financial Law
- Whistleblower Law
- Workers' Compensation
- Law School
Par Files Complaint Against the Government Claiming that FDA's Off-Label Marketing Regulations Violate the First Amendment
Par filed a Complaint for Declaratory and Injunctive Relief against the United States, the U.S. Food & Drug Administration (FDA), the Commissioner of the FDA, and the Secretary of the Department of Health & Human Services seeking a declaratory judgment that the application of FDA off-label...
Here is a copy of the off-label marketing presentation that I prepared for ACI's conference on Fraud and Abuse in the Sale and Marketing of Drugs held last week in New York. The presentation slides include: A summary chart...
The government settled 21 cases involving allegations of off-label marketing of drugs between 2004 and 2010. 95% of the government’s investigations in these 21 instances were initiated by a qui tam complaint filed pursuant to the False Claims Act. The...
Pfizer Ordered to Pay $95 Million for Deceptive Marketing of NeurontinThis posting was written by Jody Coultas, Editor of CCH State Unfair Trade Practices Law.Pharmaceutical company Pfizer, Inc. violated the California Unfair Competition Law (UCL) by marketing its prescription drug Neurontin for a...
A federal district court in the Southern District of Texas recently dismissed a qui tam False Claims Act complaint against Medtronic alleging improper off-label marketing. See United States ex rel. Bennett v. Medtronic, Inc., No. H-08-3408 (S.D. Tex. Sept. 30, 2010). Following a...